FDA approves Bristol-Myers Squibb lung cancer treatment

Organisation: Position: Deadline Date: Location:

Bristol-Myers Squibb Co has announced that the US Food and Drug Administration approved its treatment, Opdivo, for patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy.

Reuters Health reports that the drug competes with Merck & Co’s Keytruda and belongs to a class of treatments that work by activating the immune system to attack tumours.

Both treatments have racked up approvals for indications, including melanoma, lung cancer and head and neck cancer.

Bristol-Myers is quoted in the report as saying that Opdivo is the first immune-oncology treatment approved for patients with small cell lung cancer, which accounts for about 10% to 15% of all lung cancers.

Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.